prostate,serum

CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.

Orlistat-D3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat (T0686) is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat (T0686) decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (T0686) (10 mg/kg) decreases serum cholesterol levels and total bod......

5-Methoxycanthin-6-one displays moderate cytotoxic activity against the human prostate cancer cell PC-3 line, with IC50 values ranging from 13.5-15.4 uM versus doxorubicine with IC50 = 1.5 uM. It also exhibits a clear suppressive effect on the phagocytosi

IS4 is a selective competitive antagonist of CXCR4, exhibiting an IC50 of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. It remains stable in serum and is non-cytotoxic. IS4 competes with CXCL12 for binding to CXCR4, thereby inhibiting CXCL12-induced intracellular Ca2+ release and cancer cell migration. This compound is applicable in research on the prevention of metastasis in conditions such as breast cancer, prostate cancer, and leukemia.